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Abstract These days, the gut microbiota is universally rec-
ognized as an active organ that can modulate the overall host
metabolism by promoting multiple functions, from digestion
to the systemic maintenance of overall host physiology.
Dysbiosis, the alteration of the complex ecologic system of
gut microbes, is associated with and causally responsible for
multiple types of pathologies. Among the latters, metabolic
diseases such as type 2 diabetes and obesity are each distin-
guishable by a unique gut microbiota profile. Interestingly, the
specific microbiota typically found in the blood of diabetic
patients also has been observed at the level of atherosclerotic
plaque. Here, we report evidence from the literature, as well as
a few controversial reports, regarding the putative role of gut
microbiota dysbiosis-induced cardiovascular diseases, such as
atherosclerosis, which are common comorbidities of metabol-
ic dysfunction.
Keywords Gut microbiota . Cardiovascular diseases .
High-fat diet . Metagenomics . Inflammation . Protein-rich
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Introduction
Animals and microorganisms have coevolved to form a com-
plex superorganism to benefit each other with functions they
have not evolved on their own. For example, whereas micro-
organisms digest complex carbohydrates from plants and
synthesize vitamins, the human host provides nutrients from
alimentation and a protective environment. Excitingly, micro-
bial cells largely outnumber eukaryotic cells. For instance, in
humans, microbial cells are estimated to be 10 times more
numerous than eukaryotic cells [1]. Moreover, the overall
microbial genome—the metagenome—has been shown to be
organized in about 100 times more genes than our human
genome [2••], despite a molecular complexity, in terms of base
pairs, one order of magnitude lower than that of human DNA.
Furthermore, microbial gene richness is under the control of
dietary intervention, and low microbial gene diversity is prog-
nostic of increased susceptibility to metabolic alterations [3••].
For years, the role of the gut microbiota was thought to be
relegated merely to digestive function. Nowadays, however,
the gut microbiota is widely recognized as an active organ that
can modulate multiple functions of the host, from develop-
ment of the intestinal immune system to hepatic and energy
metabolism and to modulation of the brain in terms of behav-
ior development and motor activity [4].
By means of germ-free (also called axenic) murine models,
some light has been shed on the mechanisms by which the gut
microbiota modulates host metabolism with regard to diet-
induced obesity [5], energy metabolism [6], and maintenance
of intestinal physiology [7]. These mice in fact are completely
sterile from a microbial point of view, and their lack of gut
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microbiota determines a multitude of both structural and func-
tional alterations [8]. Hence, colonization (transplantation) of
axenic mice with gut microbiota issued from other animal
models (e.g., obese mice [6]) or from human stools (termed
humanization [9, 10]) may allow identification of metabolic
processes and the related molecular mechanisms under the
control of intestinal microbes. Furthermore, we and others
have shown that targeting intestinal microbiota via dietary
treatment [11], dietary fiber [12•], or antibiotics [13, 14]
ameliorated metabolic features such as glucose tolerance,
insulin sensitivity, and body weight gain and reduced the
associated chronic low-grade inflammation [15].
Our knowledge of the ecologic organization of the gut
microbiota and its alteration—dysbiosis—has increased
thanks to advances in high-throughput molecular sequencing
[16], which obviates the need for laboratory cultivation to
identify bacteria. Today, the so-called holistic “-omics” ap-
proach allows very detailed analysis of the gut microbiota at
the level of both taxonomy, identifying the microbiota (phyla
to species), and function, identifying the microbiome (gene
repertoire) [16]. For example, the Firmicutes and
Bacteroidetes are recognized as the two major bacterial phyla
populating gut microbiota, up to 90 %.
Dysbiosis of the gut microbiota has been reported for sev-
eral pathologies, such as inflammatory chronic diseases of the
intestine [17], intestinal cancer [18], and susceptibility to aller-
gy [19], and especially for metabolic diseases, such as type 2
diabetes and obesity [20]. For example, the obesity component
appears to set the tone for gut microbial dysbiosis, because any
imbalance favoring the Firmicutes has been identified as the
“bacterial signature” of obesity in humans [21] as well as in
mice [22]. On the other hand, lack of obesity in type 2 diabetic
patients is characterized by Bacteroidetes dominance [23].
Metabolic diseases are well-known common risk factors
for development of severe cardiovascular diseases (CVDs)
[24], such as atherosclerosis, stroke, and myocardial infarc-
tion. In the past decade, there has been a global increase in
CVD-induced death, mainly as the result of coronary heart
disease (7.6 million) and stroke (5.7 million) [25]. The World
Health Organization estimates about 20 million CVD deaths
in 2015, rendering CVD as the major contributor to mortality
worldwide. If we take into account only the data relative to the
USA, the situation resembles a war bulletin. In fact, it is
estimated that 3.88% of the US population older than 18 years
will have a stroke by 2030. From 2010 to 2030, the total direct
annual medical cost attributable to stroke is expected to in-
crease from $71.55 billion to $183.13 billion, with an overall
estimated increase of 129 % [26].
Recent evidence from the literature provides a link between
microbial activity and the modulation of overall
cardiometabolism. These experimental results were obtained
through metabolomics [27], the overall analysis of plasma
metabolites (metabolome), which enabled identification of
key atherogenic microbial products, such as trimethylamine
(TMA) and its hepatic-generated metabolite TMA-N-oxide
(TMAO), resulting from microbial metabolism of dietary
nutrients such as choline and L-carnitine [28••].
However, the impact of gut microbiota and its dysbiosis on
the induction of CVD remains a subject for debate because of
some controversial aspects of the molecular mechanisms un-
derlying this relationship, which are discussed in this review.
The Role of Gut Microbiota in Cardiovascular
Impairment
At the end of the 1990s, the link between gut microbiota and
CVD had not yet been discovered, and the first article to focus
on this relationship failed to demonstrate any interaction. In
this context, Wright et al. [29] reported that axenic (germ-free)
ApoE knock-out mice were not protected from the develop-
ment of atherosclerotic plaque, suggesting that the gut micro-
biota is not mandatory for the etiology of atherosclerosis. In
addition, a meta-analysis of clinical trials of antibiotic therapy
in patients with coronary artery disease (CAD) failed to dem-
onstrate any benefit with regard to the mortality or cardiovas-
cular events in CAD patients. This result suggests that gut
microbiota modification by antibiotics does not modify the
evolution of CAD [30]. In another study, 4,012 patients with
documented stable CAD received either 600 mg of
azithromycin or placebo weekly for 1 year, with no effect on
the risk of cardiac events among patients with stable CAD [31].
Nevertheless, in a Dahl S rat model of ischemia/reperfusion
injury of the heart, microbiota was shown to increase the
severity of myocardial infarction. In fact, the authors showed
that treatment with vancomycin, a very poorly absorbable
antibiotic, led to a 27 % reduction in myocardial infarction
and a 35 % increase in postischemic mechanical function
recovery. This effect was associated with a change in the gut
microbiota at both the bacterial and fungal levels and to re-
duced plasma levels of leptin. The latter datum was confirmed
mechanistically by administration of the leptin-suppressing
probiotic Lactobacillus plantarum 299v, which resulted in a
29 % reduction in myocardial infarction [32]. These first two
contradictory examples of antibiotic utilization (azithromycin
vs vancomycin) clarify the complexity of gut microbiota-based
intervention in terms of efficacy and properties of the applied
protocol. Interestingly, L. plantarum PH04 (another strain of
the aforementioned probiotic) also was described as a
cholesterol-lowering probiotic in hypercholesterolemic mice,
in which administration of this probiotic was associated with a
10-fold increase in fecal lactic acid bacteria [33].
Recently, several works highlighted a new mechanism by
which the intestinal microbiota seems to participate in the
etiology of CVD. This discovery is based on metabolomic
studies of plasma samples from patients with atherosclerotic
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plaque formation. The authors found that the concentration of
the metabolite TMAOwas elevated in patients with atheroscle-
rosis andwas correlated directly with this pathology.Moreover,
the authors demonstrated that the gut microbiota is responsible
for TMAO synthesis by converting choline, an essential nutri-
ent, into TMA. For example, bacteria from the class
Erysipelotrichia (phylum Firmicutes) reportedly can metabo-
lize choline to TMA [34], hence mimicking a choline deficien-
cy. Next, TMA is absorbed and rapidly oxidized by hepatic
cells to form TMAO [35], which is responsible for macrophage
foam cell formation, as reported in Fig. 1, by reducing reverse
cholesterol transport in vivo, and consequently promotes cho-
lesterol accumulation in the foam cells of atheroma [28••].
However, the molecular mechanisms by which TMAO reduces
reverse cholesterol transport are not well understood.
Therefore, on one hand, bacteria from the class
Erysipelotrichia may promote atherosclerosis via TMA–
TMAO production [36]. On the other hand, these bacteria
may promote nonalcoholic fatty liver disease (NAFLD) by
reducing choline availability for the synthesis of very low-
density lipoprotein in the liver, resulting in triglyceride accu-
mulation in the hepatocytes [37]. It is noteworthy that the
abundance of bacteria from the class Erysipelotrichia also
increases with an iron-rich diet, which promotes gut epithelial
cell stress via iron accumulation in the enterocytes and, con-
sequently, inflammation-induced dysbiosis of the gut micro-
biota. Hence, an iron-rich diet may be directly responsible for
the development of NAFLD and atherosclerosis via alteration
of the gut microbiota [36].
Besides the intestine, several other organs of the body, such
as the mouth, skin, vagina, and airways, harbor their own
microbiota, each with a specific bacterial proportion [38].
Interestingly, atherosclerotic plaque also has been shown to
harbor its own microbiota, dominated by members of the
phylum Proteobacteria (e.g., Escherichia coli) [39].
Remarkably, this phylum is also the most abundant of the
newly identified blood microbiota we discovered recently in
diabetic patients in the Epidemiological Study on the Insulin
Resistance Syndrome (DESIR) cohort [40••]. Therefore, it
may be speculated that the establishment of blood microbiota
might represent the first step in the kinetics of atherosclerotic
plaque formation.
Bacteria from the genus Collinsella also were found to be
enriched in patients with symptomatic atherosclerosis, defined
as the presence of stenotic atherosclerotic plaques at the level
of the carotid artery and leading to cerebrovascular events. By
Fig. 1 Gut microbiota and its impact on the cardiovascular system.
Products from a protein-rich diet, such as L-carnitine and phosphatidyl-
choline, may be metabolized into choline, which is converted to
trimethylamine (TMA) by the gut microbiota. TMAmay be oxidized into
the liver to form TMA-N-oxide (TMAO), which can promote the forma-
tion of atherosclerotic plaque [28••]. On the other hand, diet-induced gut
microbiota dysbiosis may result in bacterial translocation into the
systemic blood flow, where a blood microbiota (almost 90 % Gram-
negative bacteria) may become established [40••]. Subsequently, athero-
sclerotic plaques may develop and promote atherosclerosis and cardio-
vascular diseases. Interestingly, a plaque-specific blood-like microbiota
exists, and it is dominated by Gram-negative bacteria (Proteobacteria
phylum) as well [39]
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contrast, bacteria belonging to Roseburia and Eubacterium
were augmented in the gut microbiota of healthy controls [41].
In this study, by Karlsson et al. [41], the microbiome (func-
tional gene level) also was investigated, revealing enrichment
of genes encoding for peptidoglycan, among others, in the
metagenome from patients.
Among the strategies to target the gut microbiota, prebi-
otics [42, 43] and probiotics [44] are those used most often. In
an article published in 2014, Gan et al. proposed using
Lactobacillus rhamnosus GR-1 as a probiotic for treating
heart failure in rats subjected to 6 weeks of sustained coronary
artery occlusion. The authors showed that the probiotic treat-
ment could delay heart failure development after coronary
occlusion in rats. However, the probiotic treatment did not
affect the cecal microbiome profile [45].
In ano the r a r t i c l e , t he au tho r s showed tha t
Methanomassiliicoccus luminyensis B10, a methanogen bac-
terium, can deplete TMA by reducing it with H2 for
methanogenesis. Therefore, they suggest that bacteria from
this group may be used as probiotics to treat metabolic disease
as well as CVD by reducing TMA and, hence, TMAO plasma
levels [46]. In this context, plasma levels of choline, as well as
betaine, may be used as a prognostic value to determine the
risk of developing a major adverse cardiac event (MACE),
such as death, myocardial infarction, or stroke [47]. In this
study, Wang et al. [47] examined a 3-year survey of 3,903
sequential stable subjects who underwent elective diagnostic
coronary angiography. However, the authors reported that
values of choline and betaine are prognostic of MACE only
in association with increased TMAO plasma levels.
Besides CVD in adulthood, this disease also represents a
serious health challenge in term infants. Congenital heart
disease (CHD) is among the first causes of premature death
in the first year of life. CHD also is one of the most important
risk factors for necrotizing enterocolitis (NEC) in term infants.
Probiotic treatment with Bifidobacterium longum subsp.
infantis is reported to be effective in terms of reducing inflam-
mation in NEC, even if the gut microbiota appears not to be
significantly affected by the probiotic [48]. Interestingly, CHD
also is associated with dysbiosis of the gut microbiota, such as
reduced total bacteria, Bacteroidetes, and bifidobacteria, when
healthy infants are compared with CHD infants. Nevertheless,
administration of the probiotic Bifidobacterium infantis again
did not show a significant change in plasma cytokines or in the
microbial stool profiles of CHD infants compared with the
placebo group [49].
Periodontal Diseases, Oral Microbiota Translocation,
and CVDs
Periodontitis (also known as periodontal disease [PD]) is an
inflammatory disease of the oral cavity defined as a chronic
bacterial infection of the soft and hard tissues supporting and
surrounding the teeth and caused by Gram-negative
capnophilic bacteria [50, 51].
Besides metabolic diseases such as type 2 diabetes and
obesity, PD also is considered a risk factor for CVD. In fact,
PD has been associated with CVD and atherosclerosis [52],
suggesting that the oral microbiota may be causal in the
etiology of atherosclerosis. In this context, we recently report-
ed that 1-month colonization with periodontal pathogens such
as Porphyromonas gingivalis, Prevotella intermedia, and
Fusobacterium nucleatum aggravated high-fat diet (HFD)-
induced metabolic alteration (glucose intolerance) as well as
systolic and diastolic arterial pressure in diabetic mice [53].
The molecular mechanism underlying this phenotype is asso-
ciated with Gram− bacterial lipopolysaccharide (LPS), be-
cause we also showed that CD14 knock-out mice were
protected from HFD-induced periodontal defects [54].
The possibility that LPS might bridge PD and CVD also
was suggested by another paper showing that LPS from
Porphyromonas gingiva l i s was respons ib le for
inflammation-induced CVD via increased oxidative stress
and mitochondrial dysfunction [55].
Oral bacterial spread into the bloodstream (bacterial trans-
location) also may be the origin of PD-induced endocarditis
and myocardial and/or cerebral infarction, especially in pa-
tients with heart valve dysfunction, as the result of uncon-
trolled bacteremia [56]. For example, oral streptococci have
been found to dominate infective endocarditis [57]. Following
bacterial translocation, Calandrini et al. [58] detected the
periopathogen Aggregatibacter actinomycetemcomitans in
20 % of endarterectomy (the surgical removal of atheroscle-
rotic plaque from an artery) specimens from patients with
myocardial infarction, followed by Pseudomonas species.
However, metagenomic analysis of the oral microbiota from
15 patients with clinical atherosclerosis failed to show differ-
ences when compared with control subjects [39]. In addition,
the same study failed to demonstrate that atherosclerosis pa-
tients harbor a gut microbiota different from that of control
subjects.
Conclusions
Currently, the worldwide scientific community is paying more
attention to the putative consequences of alterations in the gut
microbiota and the progression of cardiometabolic disease,
given the pleiotropic range of host functions that may be
affected by gut microbiota dysbiosis [59, 60, 16]. Despite
convincing studies showing the deleterious effects of gut
microbiota metabolism of a protein-rich diet, gut microbiota
metabolism of L-carnitine, and the association with cardio-
vascular risk, controversy persists. In fact, it also has been
shown that L-carnitine may ameliorate metabolic diseases by
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increasing insulin sensitivity of the skeletal muscle and may
reduce ischemic heart disease. Moreover, dietary fish is rich in
TMAO, despite the beneficial effects of fish oil on cardiovas-
cular events [61].
These results demonstrate that the complex ecology of the
gut microbiota and its metabolic behavior must be considered
as being associated with specific metabolic conditions, rather
than generalized as a common mechanism of etiology.
Therefore, uncertainty remains as to whether the gut microbi-
ota should be considered a cause or consequence of a given
pathology.
The path to finding and developing microbe-based thera-
pies passes ineluctably through the elucidation of this relevant
dilemma.
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